Procedural Volume and Outcomes After Septal Reduction Therapies in Hypertrophic Obstructive Cardiomyopathy

Background Septal myectomy and alcohol septal ablation (ASA) are septal reduction therapies for patients with symptomatic obstructive hypertrophic cardiomyopathy. Operator and hospital volume may influence outcomes, but contemporary data on this relationship are limited. Methods and Results This ret...

Full description

Saved in:
Bibliographic Details
Main Authors: Nirav Patel, Naman S. Shetty, Mokshad Gaonkar, Abdulla Shahid, Girija P. Divekar, Akhil Pampana, Nehal Vekariya, Peng Li, Mustafa I. Ahmed, Garima Arora, Pankaj Arora
Format: Article
Language:English
Published: Wiley 2024-11-01
Series:Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:
Online Access:https://www.ahajournals.org/doi/10.1161/JAHA.124.036387
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1846149868858376192
author Nirav Patel
Naman S. Shetty
Mokshad Gaonkar
Abdulla Shahid
Girija P. Divekar
Akhil Pampana
Nehal Vekariya
Peng Li
Mustafa I. Ahmed
Garima Arora
Pankaj Arora
author_facet Nirav Patel
Naman S. Shetty
Mokshad Gaonkar
Abdulla Shahid
Girija P. Divekar
Akhil Pampana
Nehal Vekariya
Peng Li
Mustafa I. Ahmed
Garima Arora
Pankaj Arora
author_sort Nirav Patel
collection DOAJ
description Background Septal myectomy and alcohol septal ablation (ASA) are septal reduction therapies for patients with symptomatic obstructive hypertrophic cardiomyopathy. Operator and hospital volume may influence outcomes, but contemporary data on this relationship are limited. Methods and Results This retrospective cohort study used data from the Vizient Clinical Data Base (2016–2022). Patients with undergoing septal myectomy and ASA were identified using International Classification of Diseases, Tenth Revision, Clinical Modification (ICD‐10‐CM) codes and stratified into low‐, medium‐, and high‐volume groups based on annualized operator and hospital volumes. The outcomes were 30‐day in‐hospital mortality and 90‐day readmission, analyzed using multivariable adjusted logistic and Cox models. Among 5725 patients with hypertrophic cardiomyopathy (3990 septal myectomy; 1735 ASA), most operators and hospitals performed <10 procedures annually. For septal myectomy, low‐volume operators were associated with higher odds of 30‐day mortality (adjusted odds ratio [aOR], 1.86 [95% CI, 1.11–3.15]) and greater risk for 90‐day readmission (aOR, 1.51 [95% CI, 1.22–1.88]), and medium‐volume operators had higher odds of 30‐day mortality (aOR, 1.93 [95% CI, 1.05–3.55]). Medium‐volume hospitals had higher 30‐day mortality (aOR, 2.29 [95% CI, 1.32–3.99]), with low‐volume hospitals showing greater risk for 90‐day readmission (aOR, 1.60 [95% CI, 1.14–2.23]). For ASA, low‐ and medium‐volume operators had increased 30‐day mortality (aOR, 2.99 [95% CI, 1.15–7.75] and aOR, 3.86 [95% CI, 1.30–11.46]), but the risk of 90‐day readmission was similar. Hospital volumes did not significantly impact outcomes for ASA. Conclusions Low operator and hospital volumes were associated with worse outcomes for septal reduction therapies, emphasizing the need to refer patients with hypertrophic cardiomyopathy to high‐volume centers with experienced operators.
format Article
id doaj-art-23d88b01b58046f58fe6eadd6f5752f5
institution Kabale University
issn 2047-9980
language English
publishDate 2024-11-01
publisher Wiley
record_format Article
series Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
spelling doaj-art-23d88b01b58046f58fe6eadd6f5752f52024-11-29T09:50:51ZengWileyJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease2047-99802024-11-01132110.1161/JAHA.124.036387Procedural Volume and Outcomes After Septal Reduction Therapies in Hypertrophic Obstructive CardiomyopathyNirav Patel0Naman S. Shetty1Mokshad Gaonkar2Abdulla Shahid3Girija P. Divekar4Akhil Pampana5Nehal Vekariya6Peng Li7Mustafa I. Ahmed8Garima Arora9Pankaj Arora10Division of Cardiovascular Disease University of Alabama at Birmingham Birmingham ALDepartment of Anesthesia, Critical Care and Pain Medicine Massachusetts General Hospital Boston MADivision of Cardiovascular Disease University of Alabama at Birmingham Birmingham ALDivision of Cardiovascular Disease University of Alabama at Birmingham Birmingham ALDivision of Cardiovascular Disease University of Alabama at Birmingham Birmingham ALDivision of Cardiovascular Disease University of Alabama at Birmingham Birmingham ALDivision of Cardiovascular Disease University of Alabama at Birmingham Birmingham ALSchool of Nursing University of Alabama at Birmingham Birmingham ALDivision of Cardiovascular Disease University of Alabama at Birmingham Birmingham ALDivision of Cardiovascular Disease University of Alabama at Birmingham Birmingham ALDivision of Cardiovascular Disease University of Alabama at Birmingham Birmingham ALBackground Septal myectomy and alcohol septal ablation (ASA) are septal reduction therapies for patients with symptomatic obstructive hypertrophic cardiomyopathy. Operator and hospital volume may influence outcomes, but contemporary data on this relationship are limited. Methods and Results This retrospective cohort study used data from the Vizient Clinical Data Base (2016–2022). Patients with undergoing septal myectomy and ASA were identified using International Classification of Diseases, Tenth Revision, Clinical Modification (ICD‐10‐CM) codes and stratified into low‐, medium‐, and high‐volume groups based on annualized operator and hospital volumes. The outcomes were 30‐day in‐hospital mortality and 90‐day readmission, analyzed using multivariable adjusted logistic and Cox models. Among 5725 patients with hypertrophic cardiomyopathy (3990 septal myectomy; 1735 ASA), most operators and hospitals performed <10 procedures annually. For septal myectomy, low‐volume operators were associated with higher odds of 30‐day mortality (adjusted odds ratio [aOR], 1.86 [95% CI, 1.11–3.15]) and greater risk for 90‐day readmission (aOR, 1.51 [95% CI, 1.22–1.88]), and medium‐volume operators had higher odds of 30‐day mortality (aOR, 1.93 [95% CI, 1.05–3.55]). Medium‐volume hospitals had higher 30‐day mortality (aOR, 2.29 [95% CI, 1.32–3.99]), with low‐volume hospitals showing greater risk for 90‐day readmission (aOR, 1.60 [95% CI, 1.14–2.23]). For ASA, low‐ and medium‐volume operators had increased 30‐day mortality (aOR, 2.99 [95% CI, 1.15–7.75] and aOR, 3.86 [95% CI, 1.30–11.46]), but the risk of 90‐day readmission was similar. Hospital volumes did not significantly impact outcomes for ASA. Conclusions Low operator and hospital volumes were associated with worse outcomes for septal reduction therapies, emphasizing the need to refer patients with hypertrophic cardiomyopathy to high‐volume centers with experienced operators.https://www.ahajournals.org/doi/10.1161/JAHA.124.036387alcohol septal ablationhypertrophic cardiomyopathyseptal myectomyvolume
spellingShingle Nirav Patel
Naman S. Shetty
Mokshad Gaonkar
Abdulla Shahid
Girija P. Divekar
Akhil Pampana
Nehal Vekariya
Peng Li
Mustafa I. Ahmed
Garima Arora
Pankaj Arora
Procedural Volume and Outcomes After Septal Reduction Therapies in Hypertrophic Obstructive Cardiomyopathy
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
alcohol septal ablation
hypertrophic cardiomyopathy
septal myectomy
volume
title Procedural Volume and Outcomes After Septal Reduction Therapies in Hypertrophic Obstructive Cardiomyopathy
title_full Procedural Volume and Outcomes After Septal Reduction Therapies in Hypertrophic Obstructive Cardiomyopathy
title_fullStr Procedural Volume and Outcomes After Septal Reduction Therapies in Hypertrophic Obstructive Cardiomyopathy
title_full_unstemmed Procedural Volume and Outcomes After Septal Reduction Therapies in Hypertrophic Obstructive Cardiomyopathy
title_short Procedural Volume and Outcomes After Septal Reduction Therapies in Hypertrophic Obstructive Cardiomyopathy
title_sort procedural volume and outcomes after septal reduction therapies in hypertrophic obstructive cardiomyopathy
topic alcohol septal ablation
hypertrophic cardiomyopathy
septal myectomy
volume
url https://www.ahajournals.org/doi/10.1161/JAHA.124.036387
work_keys_str_mv AT niravpatel proceduralvolumeandoutcomesafterseptalreductiontherapiesinhypertrophicobstructivecardiomyopathy
AT namansshetty proceduralvolumeandoutcomesafterseptalreductiontherapiesinhypertrophicobstructivecardiomyopathy
AT mokshadgaonkar proceduralvolumeandoutcomesafterseptalreductiontherapiesinhypertrophicobstructivecardiomyopathy
AT abdullashahid proceduralvolumeandoutcomesafterseptalreductiontherapiesinhypertrophicobstructivecardiomyopathy
AT girijapdivekar proceduralvolumeandoutcomesafterseptalreductiontherapiesinhypertrophicobstructivecardiomyopathy
AT akhilpampana proceduralvolumeandoutcomesafterseptalreductiontherapiesinhypertrophicobstructivecardiomyopathy
AT nehalvekariya proceduralvolumeandoutcomesafterseptalreductiontherapiesinhypertrophicobstructivecardiomyopathy
AT pengli proceduralvolumeandoutcomesafterseptalreductiontherapiesinhypertrophicobstructivecardiomyopathy
AT mustafaiahmed proceduralvolumeandoutcomesafterseptalreductiontherapiesinhypertrophicobstructivecardiomyopathy
AT garimaarora proceduralvolumeandoutcomesafterseptalreductiontherapiesinhypertrophicobstructivecardiomyopathy
AT pankajarora proceduralvolumeandoutcomesafterseptalreductiontherapiesinhypertrophicobstructivecardiomyopathy